Paul Tudor Jones’s Tango Therapeutics TNGX Stock Holding History

Paul Tudor Jones’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-68,251	Closed	-$605K	–	4278
2025 Q4	$605K	Buy	68,251 +14,679	+27%	+$126K	﹤0.01%	2605
2025 Q3	$450K	Buy	+53,572	New	+$363K	﹤0.01%	2755
2025 Q2	–	Sell	-34,060	Closed	-$46.7K	–	3751
2025 Q1	$46.7K	Sell	34,060 -26,554	-44%	-$65.2K	﹤0.01%	2958
2024 Q4	$187K	Sell	60,614 -2,682	-4%	-$12.5K	﹤0.01%	2857
2024 Q3	$487K	Buy	+63,296	New	+$604K	﹤0.01%	2052
2024 Q2	–	Sell	-50,894	Closed	-$404K	–	2798
2024 Q1	$404K	Sell	50,894 -1,211	-2%	-$13K	﹤0.01%	1741
2023 Q4	$516K	Buy	+52,105	New	+$452K	﹤0.01%	1779

Other funds holding TNGX

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

Paul Tudor Jones's TNGX Position: Q1 2026 in Review

Paul Tudor Jones sold out of Tango Therapeutics (TNGX) in Q1 2026, closing a stake of 68,251 shares — an estimated $605K sold.

Paul Tudor Jones first reported a position in TNGX in Q4 2023 and held it in 7 quarters. The position peaked at $605K in Q4 2025. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

Paul Tudor Jones reported no remaining Tango Therapeutics position as of Q1 2026 after selling out during the quarter.
Paul Tudor Jones sold 68,251 Tango Therapeutics shares in Q1 2026, an estimated $605K.
Paul Tudor Jones first reported a position in Tango Therapeutics in Q4 2023 and held it in 7 quarters.
Paul Tudor Jones's Tango Therapeutics position peaked at $605K in Q4 2025.
194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.